235 related articles for article (PubMed ID: 31973229)
41. New molecularly targeted therapies against advanced hepatocellular carcinoma: From molecular pathogenesis to clinical trials and future directions.
Chuma M; Terashita K; Sakamoto N
Hepatol Res; 2015 Oct; 45(10):E1-E11. PubMed ID: 25472913
[TBL] [Abstract][Full Text] [Related]
42. miRNAs: new tools for molecular classification, diagnosis and prognosis of hepatocellular carcinoma.
Liu AM; Wang W; Luk JM
Hepat Oncol; 2014 Jun; 1(3):323-329. PubMed ID: 30190966
[TBL] [Abstract][Full Text] [Related]
43. Extracellular Vesicle-Associated mir-21 and mir-144 Are Markedly Elevated in Serum of Patients With Hepatocellular Carcinoma.
Pu C; Huang H; Wang Z; Zou W; Lv Y; Zhou Z; Zhang Q; Qiao L; Wu F; Shao S
Front Physiol; 2018; 9():930. PubMed ID: 30065664
[No Abstract] [Full Text] [Related]
44. Hepatocellular carcinoma treatment over sorafenib: epigenetics, microRNAs and microenvironment. Is there a light at the end of the tunnel?
Gnoni A; Santini D; Scartozzi M; Russo A; Licchetta A; Palmieri V; Lupo L; Faloppi L; Palasciano G; Memeo V; Angarano G; Brunetti O; Guarini A; Pisconti S; Lorusso V; Silvestris N
Expert Opin Ther Targets; 2015; 19(12):1623-35. PubMed ID: 26212068
[TBL] [Abstract][Full Text] [Related]
45. Extracellular Vesicles: A Brief Overview and Its Role in Precision Medicine.
Shang M; Ji JS; Song C; Gao BJ; Jin JG; Kuo WP; Kang H
Methods Mol Biol; 2017; 1660():1-14. PubMed ID: 28828643
[TBL] [Abstract][Full Text] [Related]
46. Recent advances in multidisciplinary management of hepatocellular carcinoma.
Gomaa AI; Waked I
World J Hepatol; 2015 Apr; 7(4):673-87. PubMed ID: 25866604
[TBL] [Abstract][Full Text] [Related]
47. Extracellular vesicles and encapusulated miRNAs as emerging cancer biomarkers for novel liquid biopsy.
Yoshioka Y; Katsuda T; Ochiya T
Jpn J Clin Oncol; 2018 Oct; 48(10):869-876. PubMed ID: 30169666
[TBL] [Abstract][Full Text] [Related]
48. Biomarkers for the early diagnosis of hepatocellular carcinoma.
Tsuchiya N; Sawada Y; Endo I; Saito K; Uemura Y; Nakatsura T
World J Gastroenterol; 2015 Oct; 21(37):10573-83. PubMed ID: 26457017
[TBL] [Abstract][Full Text] [Related]
49. Extracellular Vesicles in Cardiovascular Diseases: Alternative Biomarker Sources, Therapeutic Agents, and Drug Delivery Carriers.
Chong SY; Lee CK; Huang C; Ou YH; Charles CJ; Richards AM; Neupane YR; Pavon MV; Zharkova O; Pastorin G; Wang JW
Int J Mol Sci; 2019 Jul; 20(13):. PubMed ID: 31277271
[TBL] [Abstract][Full Text] [Related]
50. Advanced hepatocellular carcinoma. Review of targeted molecular drugs.
Alves RC; Alves D; Guz B; Matos C; Viana M; Harriz M; Terrabuio D; Kondo M; Gampel O; Polletti P
Ann Hepatol; 2011; 10(1):21-7. PubMed ID: 21301005
[TBL] [Abstract][Full Text] [Related]
51. Potentiality of immunotherapy against hepatocellular carcinoma.
Tsuchiya N; Sawada Y; Endo I; Uemura Y; Nakatsura T
World J Gastroenterol; 2015 Sep; 21(36):10314-26. PubMed ID: 26420958
[TBL] [Abstract][Full Text] [Related]
52. Review article: new therapeutic interventions for advanced hepatocellular carcinoma.
Bangaru S; Marrero JA; Singal AG
Aliment Pharmacol Ther; 2020 Jan; 51(1):78-89. PubMed ID: 31747082
[TBL] [Abstract][Full Text] [Related]
53. Radioembolisation with yttrium‒90 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH): study protocol for a randomised controlled trial.
Vilgrain V; Abdel-Rehim M; Sibert A; Ronot M; Lebtahi R; Castéra L; Chatellier G;
Trials; 2014 Dec; 15():474. PubMed ID: 25472660
[TBL] [Abstract][Full Text] [Related]
54. Single administration of Selective Internal Radiation Therapy versus continuous treatment with sorafeNIB in locally advanced hepatocellular carcinoma (SIRveNIB): study protocol for a phase iii randomized controlled trial.
Gandhi M; Choo SP; Thng CH; Tan SB; Low AS; Cheow PC; Goh AS; Tay KH; Lo RH; Goh BK; Wong JS; Ng DC; Soo KC; Liew WM; Chow PK;
BMC Cancer; 2016 Nov; 16(1):856. PubMed ID: 27821083
[TBL] [Abstract][Full Text] [Related]
55. Systemic therapy for advanced hepatocellular carcinoma: an update.
Desai JR; Ochoa S; Prins PA; He AR
J Gastrointest Oncol; 2017 Apr; 8(2):243-255. PubMed ID: 28480064
[TBL] [Abstract][Full Text] [Related]
56. Optimal therapy for patients with hepatocellular carcinoma and resistance or intolerance to sorafenib: challenges and solutions.
Ray EM; Sanoff HK
J Hepatocell Carcinoma; 2017; 4():131-138. PubMed ID: 29184856
[TBL] [Abstract][Full Text] [Related]
57. Advanced hepatocellular carcinoma: A regional cancer center experience of 48 cases.
Lokesh KN; Chaudhuri T; Lakshmaiah KC; Babu KG; Dasappa L; Jacob LA; Suresh Babu MC; Rudresha AH; Rajeev LK
Indian J Cancer; 2017; 54(3):526-529. PubMed ID: 29798951
[TBL] [Abstract][Full Text] [Related]
58. Role of regorafenib as second-line therapy and landscape of investigational treatment options in advanced hepatocellular carcinoma.
Trojan J; Waidmann O
J Hepatocell Carcinoma; 2016; 3():31-36. PubMed ID: 27703962
[TBL] [Abstract][Full Text] [Related]
59. Clinical applications of liquid biopsy as prognostic and predictive biomarkers in hepatocellular carcinoma: circulating tumor cells and circulating tumor DNA.
Li J; Han X; Yu X; Xu Z; Yang G; Liu B; Xiu P
J Exp Clin Cancer Res; 2018 Sep; 37(1):213. PubMed ID: 30176913
[TBL] [Abstract][Full Text] [Related]
60. Targeted therapy for hepatocellular carcinoma: Challenges and opportunities.
Chen S; Cao Q; Wen W; Wang H
Cancer Lett; 2019 Sep; 460():1-9. PubMed ID: 31207320
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
